Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

This single-group, Phase II study will evaluate oral psilocybin (10 mg and 25 mg; optional 10 mg booster at month 7) in 20 adults with treatment-resistant PTSD to assess safety, tolerability and preliminary clinical effect.

Psilocybin is administered as an aqueous suspension prepared on-site and taken orally. Outcomes include CAPS scores, safety measures, and feasibility for further controlled trials.